Dr. Sam Rasty is a biotech executive with more than 25 years of R&D, commercial, BD&L and operational leadership experiences spanning global large pharma, mid-cap pharma and small, private biotech companies. He has led strategy formulation, new product planning, portfolio management, fundraising, operations, R&D, manufacturing, product launch, marketing, business development and licensing transactions across multiple roles and companies in his career. A strategic and operational leader with expertise across the entire value chain of biopharmaceutical products from discovery to commercialization, he has played an active role in the development of products in multiple therapeutic areas and technology platforms including small molecules, biologics and gene & cell therapies.

He was most recently Chief Executive Officer of Sequence Bio, a Genomics and Precision Medicine company in Canada, and President and Chief Executive Officer of PlateletBio, a pioneering cell therapy biotechnology company in the Boston area.  Previously, he served as Chief Operating Officer at Homology Medicines, a genetic medicines company that he helped launch in early 2016 as a start-up and transform into a fully integrated public gene therapy and gene editing company by 2018. His earlier career spanned a variety of leadership roles at Shire plc, Endo Pharmaceuticals and GlaxoSmithKline, focused on R&D, new product planning, commercial strategy, marketing and business development.  He was a Non-Executive Director on the Board of Oxford Biomedica, a public, UK-based lentiviral gene therapy company from 2020 to 2023.  

Dr. Rasty holds a Ph.D. in Biochemistry from Louisiana State University, completed a postdoctoral research fellowship in Molecular Genetics at the University of Pittsburgh School of Medicine and received an MBA from Villanova University.